IL6 and Hyperglycemia: Consistent with previous reports, systemic improvements in hyperglycemia, insulin sensitivity, and reductions in peripheral inflammatory cytokines (e.g., TNF-α, IL-6) were observed in MSC-treated DM models [32,45].